A bivalent inactivated influenza vaccine incorporating epitope-optimized surface proteins confers cross-protective immunity against H9N2 influenza virus
Emerging Microbes & Infections·
- DOI
- 10.1080/22221751.2026.2713325
- PMID
- 42546126
- PMCID
- —
- OpenAlex
- W7172254248
- Study type
- Journal article
- Publisher
- Informa UK Limited
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The work addresses agricultural and zoonotic risk management by testing a sequence-driven vaccine strategy intended to sustain efficacy despite continuous viral mutation.
Structured evidence summary
Research question
The investigation examines whether a computationally refined bivalent inactivated formulation can generate broader immune defense against evolving H9N2 avian influenza strains compared to established reference candidates.
Study design
Researchers performed a preclinical murine trial comparing the novel chimeric vaccine against a standard candidate virus and evaluating survival outcomes after exposure to a mismatched viral isolate.
Population and setting
Laboratory mice served as the exclusive biological model for all immunogenicity assessments and pathogen challenge experiments.
Main findings
Animals administered the optimized dual-component preparation showed heightened cross-reactive antibody generation and T-cell activation relative to the comparator strain. Vaccinated subjects also maintained survival following lethal exposure to a genetically divergent H9N2 isolate and displayed diminished respiratory viral replication.
Public-health relevance
The work addresses agricultural and zoonotic risk management by testing a sequence-driven vaccine strategy intended to sustain efficacy despite continuous viral mutation.
Important limitations
The analysis depends entirely on murine models, which prevents direct translation to human immunological responses or practical application in commercial poultry operations without additional validation.
GIDS interpretation
This peer-reviewed publication documents preclinical progress in algorithm-guided influenza vaccine engineering, offering context for ongoing academic efforts to manage antigenically variable avian strains under a One Health perspective.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.